NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

The Future of Drug Development: The Economics of Pharmacogenomics

John A. Vernon, W. Keener Hughen

NBER Working Paper No. 11875
Issued in December 2005
NBER Program(s):   HE   PR

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance of uncertainty around how PG will impact the future landscape of pharmaceutical and biological R&D, we identify several likely outcomes. We conclude PG has the potential to significantly reduce both expected drug development costs (via higher probabilities of technical success, shorter clinical development times, and smaller clinical trials) and returns. The impact PG has on expected returns is partially mitigated by higher equilibrium prices, expedited product launches, and longer effective patent lives. Our conclusions are, of course, accompanied by numerous caveats.

download in pdf format
   (303 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (303 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w11875

Published: Vernon, J., Hughen K., Trujillo, A. The Future of Drug Development: The Economics of Pharmacogenomics. January 2008, Vol. 1, No. 1, Pages 49-59 Expert Review of Clinical Pharmacology

Users who downloaded this paper also downloaded these:
Abbott and Vernon w11114 The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions
Cook, Hunter, and Vernon w15723 Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures
Berndt, McGuire, and Newhouse w16879 A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets
Cockburn Is the Pharmaceutical Industry in a Productivity Crisis?
Guedj and Scharfstein w10933 Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us